However, dual-targeted CAR-T directed at GPC-3 and asialo-glycoprotein receptor (ASRG1) exerted superior anticancer activity and persistence than single-targeted CAR-T cells in two GPC3+ASGR1+HCC xenograft models [146]. Here, GPC3 is linked to hepatocellular carcinoma.